Fact CheckerSign in

NCT07561866Completed

Prognostic Impact of Diabetes and Weight Variability in Telemonitored Heart Failure

Impact of Diabetes, Short-term Weight Variability, Heart Failure Etiologies and Other Comorbidities on Survival in a National Telemonitored Heart Failure Cohort

Source: ClinicalTrials.gov · Last updated 1 May 2026

Brief summary (registry, in English)

This observational cohort study evaluates the prognostic impact of diabetes, comorbidity burden, and short-term weight variability among adults with chronic heart failure enrolled in a nationwide remote patient monitoring program in France. Patients were enrolled between September 3 2018 and April 3 2024 as part of routine heart failure care. Baseline demographic, clinical, and treatment data, along with weight measurements collected through telemonitoring, were analyzed. The study aims to assess associations between diabetes status, multimorbidity, and weight variability with survival outcomes using retrospective data from the program database. No study-mandated interventions were performed.

Status (registry)
Completed
Study type
Observational
Enrollment
16556 (actual)
First submitted
24 Apr 2026
Start date
3 Sept 2018
Primary completion date
3 Apr 2024
Lead sponsor
Satelia
NCT number
NCT07561866

What you commit to

  • Study type: Observational
  • Participants enrolled: 16556
  • From 3 Sept 2018 to the primary completion date, 3 Apr 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Missing baseline information on diabetes status

Other

  • Missing follow-up data for survival status

Who the study is looking for

  • Age 18 years or older
  • Diagnosis of chronic heart failure
  • Enrolment in the national heart failure remote monitoring program between September 3, 2018, and April 3, 2024
  • Availability of baseline clinical data including diabetes status

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Satelia
Coordinator of this site? Confirm its status
BordeauxFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.